Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

Ovarian cancer, a leading cause of death among gynecological malignancies, has a poor prognosis and low 5-year survival rate, necessitating new therapeutic strategies. CDK4/6 inhibitors show promise ...

In this context, a study appearing in Frontiers of Medicine explores the potential of dronedarone, an FDA-approved drug, in inhibiting ESCC proliferation through the CDK4/CDK6-RB1 axis ...

CDK4/6 inhibitors show promise but their efficacy varies, highlighting the need for biomarkers. This study explores TRIM4's role in ovarian cancer's response to CDK4/6 inhibitors, revealing that ...

"While we await results from ongoing prospective trials, our data suggest that treatment decisions should consider both the prior history of CDK4/6i benefit and the pattern of metastatic spread." ...

Outpatient administration of CAR T-cell therapies can reduce costs and improve patient satisfaction, with evolving ...

7 Residual cancer cells present beyond these times are likely to be resistant to treatment. Not surprisingly, women receiving the CDK4/6 inhibitors in the adjuvant setting had an increased probability ...

1) The epigenetic regulations in drug resistance. Our preliminary data revealed that epigenetic regulation is involved in the resistance to one chemotherapeutic, CDK4/6 inhibitor. We determine how an ...

The study compared camizestrant in combination with CDK4/6 inhibitor drugs – such as Pfizer's Ibrance (palbociclib), Novartis' Kisqali (ribociclib), or Eli Lilly's Verzenios (abemaciclib ...